Mode
Text Size
Log in / Sign up
Early Phase 1 N=46 Diagnostic

Assessment of Renal Function by Multiparametric MRI

Renal Impairment

Enrolled (actual)
46
Serious AEs
0.0%
Results posted
Dec 2025
Primary outcome: Primary: T1 Time — 1500 ms

Study Design & Population

Study type
Interventional
Phase
Early Phase 1
Interventions
mpMRI (Diagnostic_test)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Zurich
Primary completion
Apr 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
T1 Time
1500

Summary

Metabolic syndrome is a collection of conditions that affect at least three of the following five criteria: abdominal obesity, high blood pressure, high fasting glucose levels, high triglyceride levels, and low levels of high-density lipoprotein (HDL) cholesterol. Chronic kidney disease (CKD) is a common complication of metabolic syndrome, with an estimated prevalence of 13-40%. Early diagnosis of progressive conditions before the onset of reduced glomerular filtration rate (GFR) or albuminuria may be of clinical benefit but is not possible at present. Furthermore, the diagnosis and quantification of CKD in the context of metabolic syndrome is challenging due to the lack of reliable diagnostic biomarkers, and the current methods may not accurately reflect kidney function in patients with metabolic syndrome. Magnetic resonance imaging (MRI) has been sparsely explored as a potential tool to assess renal perfusion, oxygenation, and fibrosis. Multiparametric MRI (mpMRI) combines several different imaging techniques to provide a more comprehensive evaluation of tissue structure and function. These techniques hold promise for non-invasive assessment of kidney function, but their clinical utility is still largely experimental. Therefore, we aim to conduct an exploratory study to investigate the reliability, reproducibility as well as the validity of parameters for kidney function of multiparametric MRI as well as compare these parameters in between healthy patients and patients with metabolic syndrome.

Eligibility Criteria

Inclusion Criteria

  • Diagnosed metabolic syndrome

Exclusion Criteria

  • MRI exclusion criteria
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT06407375). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search